Table 2.

Measures of association between EPs and the development of CDMS

Author (Year)TechniqueSensitivity, %Specificity, %PPV %NPVc, %Relative risk CDMS95% CI relative riskTau, %
Values in parentheses represent parameters from clinically silent lesions only.
Not significant at p < 0.05.
PPV = positive predictive value; NPVc = complement of the negative predictive value; relative risk of CDMS = PPV/NPVc; VEP = visual evoked potential; SEP = somatosensory evoked potential; BAEP = brainstem auditory evoked potential; EP = evoked potential.
Filippini et al. (1994)14VEP256325.938.20.680.33-1.401.5*
SEP (tibial)17.98741.732.91.270.60-2.680.4*
SEP (median)14.392.65032.41.540.72-3.320.1*
BAEP17.990.75031.91.570.77-3.171.2*
Lee et al. (1991, 1988)15,16VEP60.780.543.717.52.491.52-4.088.1
SEP36.440.320.640.20.510.32-0.824.6
Hume and Waxman (1988)18VEP83 (75.8)78.5 (85.9)52.7 (54.3)5.9 (5.9)8.96 (9.24)4.42-18.228.8 (29.9)
SEP63 (41.4)76.6 (89.7)42 (44.4)11.5 (11.5)3.87 (3.87)2.09-7.1512.1 (10.2)
BAEP14.6 (14.6)97.6 (97.6)60 (60)17.9 (17.9)3.52 (3.34)2.23-5.555.1 (5.1)
Multimodal EPs89.6 (86.1)66.7 (77.3)42.6 (47.7)4.1 (4.1)10.3 (11.5)4.2-25.021.6 (27.6)
Matthews et al. (1982)22VEP53.6 (50.0)87.8 (92.3)75 (81.3)26.5 (26.5)2.83 (3.06)1.66-4.8020 (23.1)
SEP35.7 (14.3)92.7 (100)76.9 (100)32.1 (30.5)2.39 (3.28)1.48-3.8812.7 (9.9)
BAEP21.4 (21.4)90.2 (92.5)60 (66.7)37.3 (37.3)1.61 (1.79)0.80-2.952.7*(4.1*)
Multimodal EPs60.7 (56.0)80.5 (87.2)68 (73.7)25.2 (24.4)2.72 (3.01)1.53-4.8517.7 (21.2)